Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of (11)C-Labeled ALK2 Inhibitors

Autor Murrell, Emily, Tong, Junchao, Smil, David, Kiyota, Taira, Aman, Ahmed M., Isaac, Methvin B., Watson, Iain D. G., Vasdev, Neil
Vydáno v ACS Med Chem Lett (2021)

Antagonists of the serotonin receptor 5A target human breast tumor initiating cells

Autor Gwynne, William D., Shakeel, Mirza S., Girgis-Gabardo, Adele, Kim, Kwang H., Ford, Emily, Dvorkin-Gheva, Anna, Aarts, Craig, Isaac, Methvin, Al-awar, Rima, Hassell, John A.
Vydáno v BMC Cancer (2020)

Sorafenib as an Inhibitor of RUVBL2

Autor Nano, Nardin, Ugwu, Francisca, Seraphim, Thiago V., Li, Tangzhi, Azer, Gina, Isaac, Methvin, Prakesch, Michael, Barbosa, Leandro R. S., Ramos, Carlos H. I., Datti, Alessandro, Houry, Walid A.
Vydáno v Biomolecules (2020)

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

Autor Babichev, Yael, Kabaroff, Leah, Datti, Alessandro, Uehling, David, Isaac, Methvin, Al-awar, Rima, Prakesch, Michael, Sun, Ren X., Boutros, Paul C., Venier, Rosemarie, Dickson, Brendan C., Gladdy, Rebecca A.
Vydáno v J Transl Med (2016)

Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma

Autor Ensan, Deeba, Smil, David, Zepeda-Velázquez, Carlos A., Panagopoulos, Dimitrios, Wong, Jong Fu, Williams, Eleanor P., Adamson, Roslin, Bullock, Alex N., Kiyota, Taira, Aman, Ahmed, Roberts, Owen G., Edwards, Aled M., O’Meara, Jeff A., Isaac, Methvin B., Al-awar, Rima
Vydáno v J Med Chem (2020)